Fighting around the globe, American soldiers were at high risk for contracting malaria, yet quinine - a natural cure - became hard to acquire. This historical study shows the roots and branches of an enormous drug development project during World War II.

For more than 50 years, low-cost antimalarial drugs silently saved millions of lives and cured billions of debilitating infections. Today, however, these drugs no longer work against the deadliest form of malaria that exists throughout the world. Malaria deaths in sub-Saharan Africaâ€"currently just over one million per yearâ€"are rising because of increased resistance to the old, inexpensive drugs. Although effective new drugs called "artemisinins" are available, they are unaffordable for the majority of the affected population, even at a cost of one dollar per course. Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance examines the history of malaria treatments, provides an overview of the current drug crisis, and offers recommendations on maximizing access to and effectiveness of antimalarial drugs. The book finds that most people in endemic countries will not have access to currently effective combination treatments, which should include an artemisinin, without financing from the global community. Without funding for effective treatment, malaria mortality could double over the next 10 to 20 years and transmission will intensify.

A fascinating and shocking historical exposé, The Malaria Project is the story of America's secret mission to combat malaria during World War II—a campaign modeled after a German project which tested experimental drugs on men gone mad from syphilis. American war planners, foreseeing the tactical need for a malaria drug, recreated the German model, then grew it tenfold. Quickly becoming the biggest and most important medical initiative of the war, the project tasked dozens of the country’s top research scientists and university labs to find a treatment to remedy half a million U.S. troops incapacitated by malaria. Spearheading the new U.S. effort was Dr. Lowell T. Coggeshall, the son of a poor Indiana farmer whose persistent drive and curiosity led him to become one of the most innovative thinkers in solving the malaria problem. He recruited private corporations, such as today's Squibb and Eli Lilly, and the nation’s best chemists out of Harvard and Johns Hopkins to make novel compounds that skilled technicians tested on birds. Giants in the field of clinical research, including the future NIH director James Shannon, then tested the drugs on mental health patients and convicted criminals—including infamous murderer Nathan Leopold. By 1943, a dozen strains of malaria brought home in the veins of sick soldiers were injected into these human guinea pigs for drug studies. After hundreds of trials and many deaths, they found their “magic bullet,” but not in a U.S. laboratory. America 's best weapon against malaria, still used today, was captured in battle from the Nazis. Called chloroquine, it went on to save more lives than any other drug in history. Karen M. Masterson, a journalist turned malaria researcher, uncovers the complete story behind this dark tale of science, medicine and war. Illuminating, riveting and surprising, The Malaria Project captures the ethical perils of seeking treatments for disease while ignoring the human condition.

Malaria is making a dramatic comeback in the world. The disease is the foremost health challenge in Africa south of the Sahara, and people traveling to malarious areas are at increased risk of malaria-related sickness and death. This book examines the prospects for bringing malaria under control, with specific recommendations for U.S. policy, directions for research and program funding, and appropriate roles for federal and international agencies and the medical and public health communities. The volume reports on the current status of malaria research, prevention, and control efforts worldwide. The authors present study results and commentary on the: Nature, clinical manifestations, diagnosis, and epidemiology of malaria. Biology of the malaria parasite and its vector. Prospects for developing malaria vaccines and improved treatments. Economic, social, and behavioral factors in malaria control.